PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Vardenafil - Erectile dysfunction

PAD Profile : Vardenafil - Erectile dysfunction

Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence, PDE5, PDE-5
Brand Names Include :
Levitra

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN have agreed an updated erectile dysfunction treatment pathway and associated policy statement. Please see  below for further information. There is no place in therapy recommended for vardenafil and this drug will be considered BLACK on the traffic light system.

Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use. (See here for further information https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/4691

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More